Antiretroviral therapy is able to effectively control but not eradicate HIV infection, which can
persist, leading to the need for lifelong therapy. The existence of latently HIV-infected cells is …

Introduction HIV-infected cells may rebound due to the existence of the silent HIV-infected
memory CD4+ T cells (HIV latency). This HIV latency makes the disease almost incurable. In …

HIV remains incurable due to the persistence of a latent viral reservoir found in HIV-infected
cells, primarily resting memory CD4+ T cells. Depletion of this reservoir may be the only way …

Clinical trials investigating histone deacetylase inhibitors (HDACi) to reverse HIV-1 latency
aim to expose reservoirs in antiretroviral (ARV)-treated individuals to clearance by immune …

Combinations of drugs that affect distinct mechanisms of HIV latency aim to induce robust
latency reversal leading to cytopathicity and elimination of the persistent HIV reservoir. Thus …

Histone deacetylase inhibitors and HIV latency : Current Opinion in HIV and AIDS Histone
deacetylase inhibitors and HIV latency : Current Opinion in HIV and AIDS Log in or Register …

Antiretroviral therapy (ART) can control human immunodeficiency virus-1 (HIV-1) replication
in infected individuals. Unfortunately, patients remain persistently infected owing to the …

Current antiretroviral therapies used for HIV management do not target latent viral reservoirs
in humans. The experimental “shock-and-kill” therapeutic approach involves use of latency …

Histone deacetylase (HDAC) inhibitors (HDACis) have been widely tested in clinical trials for
their ability to reverse HIV latency but have yielded only limited success. One HDACi …

HIV persistence in latently infected, resting CD4+ T cells is broadly considered a barrier to
eradicate HIV. Activation of the provirus using latency-reversing agents (LRAs) followed by …